Abstract
Membranous nephropathy is a histopathological type of renal disease, characterized by the thickening of glomerular basement membrane caused by an accumulation of immune deposits on the outer aspect of the glomerular basement membrane. Its main clinical manifestations are nephrotic syndrome or asymptomatic proteinuria. Rituximab is a murine/human chimeric anti-CD20 monoclonal antibody that depletes B cells. In recent years, rituximab has been applied to the treatment of membranous nephropathy and achieved good effects. The nephrology expert panel of the Peking University Health Science Center formed this consensus by searching PubMed, China National Knowledge Infrastructure database, Wanfang database, VIP database and other relevant literature, and combining the current situation in China, so as to standardize the clinical application of rituximab in the treatment of membranous nephropathy and provide practical guidance for clinicians.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
